Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $165

Benzinga Newsdesk www.benzinga.com Positive 87.5%

Neg 0% Neu 0% Pos 87.5%

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $150 to $165.